Notable Price Action: Is GlaxoSmithKline plc (ADR) a Buy? The Stock Rises Again

Notable Price Action: Is GlaxoSmithKline plc (ADR) a Buy? The Stock Rises Again

The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) is a huge mover today! About 2.14M shares traded hands. GlaxoSmithKline plc (ADR) (NYSE:GSK) has risen 8.98% since March 1, 2016 and is uptrending. It has underperformed by 0.27% the S&P500.
The move comes after 9 months positive chart setup for the $105.75B company. It was reported on Oct, 4 by Barchart.com. We have $54.13 PT which if reached, will make NYSE:GSK worth $26.44 billion more.

Analysts await GlaxoSmithKline plc (ADR) (NYSE:GSK) to report earnings on October, 26. They expect $0.77 earnings per share, up 8.45% or $0.06 from last year’s $0.71 per share. GSK’s profit will be $1.88 billion for 14.06 P/E if the $0.77 EPS becomes a reality. After $0.70 actual earnings per share reported by GlaxoSmithKline plc (ADR) for the previous quarter, Wall Street now forecasts 10.00% EPS growth.

GlaxoSmithKline plc (ADR) (NYSE:GSK) Ratings Coverage

Out of 10 analysts covering GlaxoSmithKline (NYSE:GSK), 5 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 50% are positive. GlaxoSmithKline has been the topic of 15 analyst reports since September 8, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Thursday, July 14 by Jefferies. The rating was upgraded by Bryan Garnier & Cie on Wednesday, January 27 to “Buy”. Argus Research maintained the shares of GSK in a report on Monday, December 7 with “Buy” rating. The company was upgraded on Monday, October 12 by JP Morgan. The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) has “Buy” rating given on Friday, August 12 by Argus Research. The firm earned “Hold” rating on Friday, February 26 by Cantor Fitzgerald. The rating was upgraded by Bank of America on Tuesday, September 8 to “Neutral”. The firm has “Underperform” rating by BNP Paribas given on Wednesday, September 14. BNP Paribas upgraded GlaxoSmithKline plc (ADR) (NYSE:GSK) on Tuesday, September 15 to “Neutral” rating. The firm has “Overweight” rating by Piperjaffray given on Friday, September 23.

According to Zacks Investment Research, “GlaxoSmithKline is one of the world’s leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.”

More important recent GlaxoSmithKline plc (ADR) (NYSE:GSK) news were published by: Businessfinancenews.com which released: “GlaxoSmithKline plc (ADR) Earning Release; Here’s What to Expect” on July 26, 2016, also Businessfinancenews.com published article titled: “GlaxoSmithKline plc (ADR) Moves Ahead in COPD Treatment”, Businessfinancenews.com published: “Can GlaxoSmithKline plc (ADR) Subsist Advair’s Patent Expiry” on June 25, 2016. More interesting news about GlaxoSmithKline plc (ADR) (NYSE:GSK) was released by: Businessfinancenews.com and their article: “Here is How the US Congress Bill Benefit GlaxoSmithKline plc (ADR), Inovio …” with publication date: April 14, 2016.

GSK Company Profile

GlaxoSmithKline plc (GSK), incorporated on December 6, 1999, is a healthcare company. The Firm is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in various therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines and human immunodeficiency virus (HIV). The Company’s divisions include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment